Costs per molecule are still rising relentlessly and the number of new medicines reaching the market remains broadly flat. Why?
Our research suggests a distinct problem is scientific and we think three changes would make a big difference.
- The industry should rebalance its expenditure and invest more in the early part of the R&D process to understand the molecular basis of disease and the role specific mechanisms play.
- Companies should become more selective about the therapeutic areas they cover and bolster their expertise by hiring or collaborating with the best people in their chosen fields of research.
- Every company should devise a clear path to clinical proof of concept for all compounds entering development and test them in humans as soon as possible, using the best tools for selecting subjects and endpoints.